Portage Biotech Announces Completion of $2.15 Million Private Financing

Core Points - Portage Biotech, Inc. has completed a private placement of $2.15 million from two directors, selling 524,390 ordinary shares at $4.10 per share, which was the Nasdaq official closing price on January 22, 2025 [1] - The proceeds from the financing will be used for working capital and other general corporate purposes for Portage and its subsidiaries [2] - Portage Biotech is a clinical-stage immuno-oncology company focused on advancing a pipeline of novel biologics aimed at enhancing the immune system's ability to combat cancer [3]